Tenax Therapeutics (TENX) Getting Somewhat Positive Media Coverage, Study Shows

News articles about Tenax Therapeutics (NASDAQ:TENX) have trended somewhat positive this week, Accern reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tenax Therapeutics earned a daily sentiment score of 0.02 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 46.4421110376448 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of NASDAQ:TENX traded down $0.01 during trading on Thursday, reaching $6.13. The stock had a trading volume of 561 shares, compared to its average volume of 208,257. Tenax Therapeutics has a 1-year low of $4.40 and a 1-year high of $15.80.

Separately, ValuEngine raised Tenax Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, February 27th.

About Tenax Therapeutics

Tenax Therapeutics, Inc, a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.

Insider Buying and Selling by Quarter for Tenax Therapeutics (NASDAQ:TENX)

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply